FDA Approves Ocrelizumab for Pediatric Relapsing MS

The FDA approval makes ocrelizumab a new treatment option for children aged 10 years and older with relapsing-remitting multiple sclerosis.
Medscape Medical News

Source link : https://www.medscape.com/viewarticle/fda-approves-ocrelizumab-pediatric-relapsing-ms-2026a1000f5m?src=rss

Author :

Publish date : 2026-05-11 19:07:00

Copyright for syndicated content belongs to the linked Source.

M	T	W	T	F	S	S
				1	2	3
4	5	6	7	8	9	10
11	12	13	14	15	16	17
18	19	20	21	22	23	24
25	26	27	28	29	30	31

FDA Approves Ocrelizumab for Pediatric Relapsing MS

Hantavirus Webinar May 12: What You Need to Know

Food-as-Medicine Intervention Signals BP Benefit in High-Risk Adults

Related Posts

When a Patient Portal Alone Won’t Suffice

Medicaid Expansion Tied to Lower Mortality Among Young Adults With Kidney Failure

White House, HHS Debut Website for Expectant and New Moms

American Hantavirus Cruise Passenger Develops Symptoms, Transferred to Atlanta

Pediatrics Group Issues New Guidance on Recess for the First Time in 13 Years

More Evidence that GLP-1s May Reduce Risk of Vision-Robbing Eye Diseases

When a Patient Portal Alone Won’t Suffice

Medicaid Expansion Tied to Lower Mortality Among Young Adults With Kidney Failure

White House, HHS Debut Website for Expectant and New Moms

American Hantavirus Cruise Passenger Develops Symptoms, Transferred to Atlanta

Pediatrics Group Issues New Guidance on Recess for the First Time in 13 Years

More Evidence that GLP-1s May Reduce Risk of Vision-Robbing Eye Diseases

Food-as-Medicine Intervention Signals BP Benefit in High-Risk Adults

FDA Approves Ocrelizumab for Pediatric Relapsing MS

Categories

Archives